Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-551-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$74.91 million
Profitability
Miscellaneous
Employees1,065
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.04. The biopharmaceutical company had revenue of $38.20 million for the quarter, compared to analyst estimates of $42.24 million. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The business's revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.61) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
16 brokerages have issued 12-month price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $150.00. On average, they anticipate Alnylam Pharmaceuticals' stock price to reach $112.75 in the next year. This suggests a possible upside of 37.6% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.
What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alnylam incurred wider-than-expected loss and missed on revenues in the second quarter of 2019. The company demonstrated progress in the global commercialization of Onpattro. The FDA set an action date of Feb 20, 2020, and the company showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy. In the second half of 2019, the company expects pivotal data read-outs from two programs on inclisiran and lumasiran . The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, currently it depends heavily on Onpattro for growth, which is a concern. The company is heavily reliant on its partnerships for supporting operations." (9/18/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
News headlines about ALNY stock have trended somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Alnylam Pharmaceuticals.
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Alnylam Pharmaceuticals own?
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
- Mr. Barry E. Greene, Pres (Age 56)
- Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
- Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
- Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.17%), Rhenman & Partners Asset Management AB (0.06%), Nisa Investment Advisors LLC (0.04%), Gulf International Bank UK Ltd (0.03%), Assenagon Asset Management S.A. (0.02%) and DNB Asset Management AS (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which institutional investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Nelson Van Denburg & Campbell Wealth Management Group LLC and Meeder Asset Management Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include John Maraganore and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which institutional investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Assenagon Asset Management S.A., DNB Asset Management AS, Gulf International Bank UK Ltd, Sumitomo Mitsui DS Asset Management Company Ltd and City Holding Co.. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $81.97.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $9.12 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.
What is Alnylam Pharmaceuticals' official website?
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
